Vasculitis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials

Vascular Lab Resource (VLR) Biorepository
Conditions:   Cardiovascular Diseases;   Metabolic Disease;   Peripheral Artery Disease;   Carotid Disease;   Aneurysmal Disease;   Venous Disease;   Thrombosis;   Lymphedema;   Lipedema;   Non-Atherosclerotic Chronic Arterial Occlusive Disease;   Vasculitis;   Fibromuscular Dysplasia;   A rterial Dissection;   May-Thurner Syndrome;   Thoracic Outlet Syndrome;   Vasospasm Intervention:   Sponsor:   The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials